Slide 1HIV/HCV Coinfection News – HCV Protease Inhibitors Juergen Rockstroh, MD Marc Poliquin, MD Slide 2 Efficacy of HCV Protease Inhibitors in Co-Infected Patients Telaprevir…

Slide 1 Slide 2 Bloodborne Pathogens/TB An OSHA Mandated Drill Slide 3 Introduction OSHA mandates that upon hire each individual who works in a high-risk environment must…

1.   2. Hepatocellular & Pancreatic Carcinomas Moving Forward with Targeted Therapy &New AgentsRaúl H. Morales - Borges, MD, FICPS, FIACATH Chairman of the Board…

1. Hepatitis C 2. Characteristics RNA virus + sense 9.6 Kb in length Flaviviridae -> hepaciviridae -> HCV 3.   4. HCV, HBV, HIV:Prevalence vs Undiagnosed Cases * Extrapolated…

1. Ibogaine in the treatment of chronic hepatitis C Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NYhttp://www.doraweiner.org 6th National Conference…

1. Ibogaine in the treatment of chronic hepatitis C Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NYhttp://www.doraweiner.org Invitational Ibogaine forum…

1. CarrollB.Leevy,M.D. NewJerseyMedicalSchool LiverCenter andSammy Davis Jr. National Liver Institute Newark,NewJersey Update on Pathobiology and Treatment of HepatitisC…

Slide 1Treatment and access to treatment in low and middle income countries Adeeba Kamarulzaman University of Malaya Kuala Lumpur, Malaysia ANRS-NIDA Joint Satellite Drug…

Slide 1HCV response to treatment in IDUs (PWID) in the Czech Republic Vratislav Rehak Remedis Clinic, Prague, Czech Republic 1 Institute of Public Health “Dr. Milan Jovanovic…

Slide 1 Dr. Alipour Slide 2  Chronic hepatitis C virus (HCV) infection is one of the most common chronic liver disease and accounts for 8000 to 13,000 deaths each year.…